NCT02657330View on ClinicalTrials.gov

Study of SBP-101 in Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Pancreatic CancerDuctal Adenocarcinoma of the Pancreas
Interventions
DRUG

SBP-101

Subcutaneous drug, escalating dose cohorts

Trial Locations (4)

3084

Austin Hospital, Heidelberg

5037

Ashford Cancer Centre, Kurralta Park

85258

HonorHealth Research Institute, Scottsdale

85259-5499

Mayo Clinic, Scottsdale

Sponsors
All Listed Sponsors
lead

Panbela Therapeutics, Inc.

INDUSTRY

NCT02657330 - Study of SBP-101 in Pancreatic Cancer | Biotech Hunter | Biotech Hunter